BRD4-mediated repression of p53 is a target for combination therapy in AML

Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BE...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Nat Commun
मुख्य लेखकों: Latif, Anne-Louise, Newcombe, Ashley, Li, Sha, Gilroy, Kathryn, Robertson, Neil A., Lei, Xue, Stewart, Helen J. S., Cole, John, Terradas, Maria Terradas, Rishi, Loveena, McGarry, Lynn, McKeeve, Claire, Reid, Claire, Clark, William, Campos, Joana, Kirschner, Kristina, Davis, Andrew, Lopez, Jonathan, Sakamaki, Jun-ichi, Morton, Jennifer P., Ryan, Kevin M., Tait, Stephen W. G., Abraham, Sheela A., Holyoake, Tessa, Higgins, Brian, Huang, Xu, Blyth, Karen, Copland, Mhairi, Chevassut, Timothy J. T., Keeshan, Karen, Adams, Peter D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2021
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801601/
https://ncbi.nlm.nih.gov/pubmed/33431824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-20378-8
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन